| Ibrutinib and venetoclax for first-line treatment of CLL N Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ... New England Journal of Medicine 380 (22), 2095-2103, 2019 | 487 | 2019 |
| Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study N Daver, G Garcia-Manero, S Basu, PC Boddu, M Alfayez, JE Cortes, ... Cancer discovery 9 (3), 370-383, 2019 | 449 | 2019 |
| Clinical experience with the BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies CD DiNardo, CR Rausch, C Benton, T Kadia, N Jain, N Pemmaraju, ... American journal of hematology 93 (3), 401-407, 2018 | 418 | 2018 |
| Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm N Pemmaraju, AA Lane, KL Sweet, AS Stein, S Vasu, W Blum, DA Rizzieri, ... New England Journal of Medicine 380 (17), 1628-1637, 2019 | 350 | 2019 |
| International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease F Van Rhee, P Voorhees, A Dispenzieri, A Fosså, G Srkalovic, M Ide, ... Blood, The Journal of the American Society of Hematology 132 (20), 2115-2124, 2018 | 316 | 2018 |
| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study E Jabbour, H Kantarjian, F Ravandi, D Thomas, X Huang, S Faderl, ... The Lancet Oncology 16 (15), 1547-1555, 2015 | 299 | 2015 |
| Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials K Sasaki, SS Strom, S O'Brien, E Jabbour, F Ravandi, M Konopleva, ... The Lancet Haematology 2 (5), e186-e193, 2015 | 291 | 2015 |
| 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ... The Lancet Haematology 7 (10), e724-e736, 2020 | 242 | 2020 |
| Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients AE Frankel, JH Woo, C Ahn, N Pemmaraju, BC Medeiros, HE Carraway, ... Blood, The Journal of the American Society of Hematology 124 (3), 385-392, 2014 | 234 | 2014 |
| Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single … E Jabbour, NJ Short, F Ravandi, X Huang, N Daver, CD DiNardo, ... The Lancet Haematology 5 (12), e618-e627, 2018 | 223 | 2018 |
| Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase … H Kantarjian, F Ravandi, NJ Short, X Huang, N Jain, K Sasaki, N Daver, ... The Lancet Oncology 19 (2), 240-248, 2018 | 215 | 2018 |
| Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, L Xiao, T Kadia, ... Journal of Clinical Oncology 39 (25), 2768-2778, 2021 | 207 | 2021 |
| Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax J Montero, J Stephansky, T Cai, GK Griffin, L Cabal-Hierro, K Togami, ... Cancer discovery 7 (2), 156-164, 2017 | 199 | 2017 |
| Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia K Morita, HM Kantarjian, F Wang, Y Yan, C Bueso-Ramos, K Sasaki, ... Journal of Clinical Oncology 36 (18), 1788, 2018 | 181 | 2018 |
| Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN E Jabbour, NJ Short, G Montalban-Bravo, X Huang, C Bueso-Ramos, ... Blood, The Journal of the American Society of Hematology 130 (13), 1514-1522, 2017 | 177 | 2017 |
| Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: a propensity … K Sasaki, EJ Jabbour, F Ravandi, NJ Short, DA Thomas, ... Cancer 122 (23), 3650-3656, 2016 | 176 | 2016 |
| Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors P Jain, H Kantarjian, KP Patel, GN Gonzalez, R Luthra, RK Shamanna, ... Blood, The Journal of the American Society of Hematology 127 (10), 1269-1275, 2016 | 172 | 2016 |
| Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells DT Saenz, W Fiskus, Y Qian, T Manshouri, K Rajapakshe, K Raina, ... Leukemia 31 (9), 1951-1961, 2017 | 171 | 2017 |
| COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials A Desai, JF Gainor, A Hegde, AM Schram, G Curigliano, S Pal, SV Liu, ... Nature reviews Clinical oncology 18 (5), 313-319, 2021 | 151 | 2021 |
| Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects N Pemmaraju, MF Munsell, GN Hortobagyi, SH Giordano Annals of oncology 23 (6), 1471-1474, 2012 | 145 | 2012 |
